BofA raised the firm’s price target on NeoGenomics (NEO) to $13 from $11 and keeps a Neutral rating on the shares. The firm is updating it price targets for Life Sciences & Diagnostic Tools stocks under its coverage, the analyst tells investors. Headwinds are expected to fade, and markets are expected to normalize in 2026, firm adds. The firm believes the biggest upside for the sector will be a return to spending by Biopharma, leading BofA to favor companies with higher exposure to research and development.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics announce Natera withdrawal of appeal in patent litigation
- NeoGenomics price target raised to $12 from $11 at Piper Sandler
- NeoGenomics to present RaDaR ST bridging study at ISLB 2025
- NeoGenomics price target raised to $11 from $6.50 at BofA
- NeoGenomics Reports Strong Revenue Growth Amid Rising Losses